Share

January 2020; 7 (1) EditorialOpen Access

Treating muscle-specific kinase myasthenia gravis from the inside out

Maartje G. Huijbers, Jan J.G.M. Verschuuren
First published December 12, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000646
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1137

Share

Article Information

vol. 7 no. 1 e646
DOI: 
https://doi.org/10.1212/NXI.0000000000000646
PubMed: 
31831572
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 28, 2019
  • Accepted in final form October 30, 2019
  • First Published December 12, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Maartje G. Huijbers, PhD and
    2. Jan J.G.M. Verschuuren, MD, PhD
  1. Maartje G. Huijbers, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. I am co-inventor on several patent applications related to MuSK MG pathogenesis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Jan J.G.M. Verschuuren, MD, PhD
    3. Scientific Advisory Boards:

    1. Myasthenia Foundation of America (MGFA) medical/scientific advisory board. Study Steering Committee of Argenx. Advisory meeting for Rapharma. All reimbursements were received by the LUMC.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. World Muscle Society, travel grant for keynote speaker lecture

    Editorial Boards:

    1. Journal of Neuromuscular Diseases, member editorial board, 2014-now

    Patents:

    1. Patents on MuSK myasthenia gravis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. The Neurology department of the LUMC has received fees from Alexion, Argen-X, and Rapharma because of consultancies

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. The LUMC received support from Argenx for research on autoimmune myasthenia gravis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. rinces Beatrix Spierfonds, grant for MG research, Prinicpal investigator.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. The LUMC received royalties for a diagnostic antibody test from TECAN/IBL.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (M.G.H., J.J.G.M.V.) and Department of Human Genetics (M.G.H.), Leiden University Medical Center, The Netherlands.
  1. Correspondence
    Dr. Verschuuren J.J.G.M.Verschuuren{at}lumc.nl

Article usage

Article usage: December 2019 to October 2023

AbstractFullPdfSource
Dec 20193372269Highwire
Jan 202017298166Highwire
Feb 2020177568Highwire
Mar 2020175337Highwire
Apr 202074619Highwire
May 2020246729Highwire
Jun 202034110Highwire
Jul 202002713Highwire
Aug 20204238Highwire
Sep 202083514Highwire
Oct 20203409Highwire
Nov 20201479Highwire
Dec 20203465Highwire
Jan 202114010Highwire
Feb 202114313Highwire
Mar 20210509Highwire
Apr 202115312Highwire
May 20212568Highwire
Jun 202104915Highwire
Jul 2021115811Highwire
Aug 2021012613Highwire
Sep 2021036625Highwire
Oct 2021127825Highwire
Nov 2021011923Highwire
Dec 202118016Highwire
Jan 202208718Highwire
Feb 202218815Highwire
Mar 202209518Highwire
Apr 202205214Highwire
May 202207818Highwire
Jun 202215113Highwire
Jul 20220608Highwire
Aug 202218712Highwire
Sep 2022011717Highwire
Oct 2022012518Highwire
Nov 2022112427Highwire
Dec 202207610Highwire
Jan 2023010516Highwire
Feb 202319515Highwire
Mar 202317012Highwire
Apr 202309410Highwire
May 202316516Highwire
Jun 202326210Highwire
Jul 202315812Highwire
Aug 20230488Highwire
Sep 20231419Highwire
Oct 20230235Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles